First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

BACKGROUND: In preclinical studies, combining M9241 (a novel immunocytokine containing interleukin (IL)-12 heterodimers) with avelumab (anti-programmed death ligand 1 antibody) resulted in additive or synergistic antitumor effects. We report dose-escalation and dose-expansion results from the phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Strauss, Julius, Deville, Jean-Laurent, Sznol, Mario, Ravaud, Alain, Maruzzo, Marco, Pachynski, Russell K, Gourdin, Theodore S, Maio, Michele, Dirix, Luc, Schlom, Jeffrey, Donahue, Renee N, Tsai, Yo-Ting, Wang, XiaoZhe, Vugmeyster, Yulia, Beier, Frank, Seebeck, Joerg, Schroeder, Andreas, Chennoufi, Sarah, Gulley, James L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230972/
https://www.ncbi.nlm.nih.gov/pubmed/37236636
http://dx.doi.org/10.1136/jitc-2022-005813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230972/
https://www.ncbi.nlm.nih.gov/pubmed/37236636
http://dx.doi.org/10.1136/jitc-2022-005813

Ejemplares similares